Shannon Welner, PA
Medical · Verona, NJNPI 1497966980
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $135,378 of the $175,892 with a category attached, or 77.0%. 32 manufacturers reported payments, led by Galderma Laboratories, L.p. at 51.7% of the total. 2025 is the largest year on record at $73,057, 7.7 times the $9,467 reported in 2021. Among medical clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,700 payments — averaging $103.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$91K
- Incyte Corporation$24K
- Organon$24K
- AbbVie$15K
- Botanix SB Inc$4K
- Johnson & Johnson$3K
- plus $15K from 26 others
What the payments were for
- Consulting fees$2,3131%
- Speaking & faculty fees$135,37877%
- Travel & lodging$7,9765%
- Food & beverage$29,55117%
- Education$6750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 236 | $90,884 |
| Incyte Corporation | 145 | $23,695 |
| Organon | 56 | $23,629 |
| AbbVie | 299 | $15,121 |
| Botanix SB Inc | 21 | $4,330 |
| Johnson & Johnson | 104 | $2,886 |
| Sanofi | 41 | $2,420 |
| Sun Pharmaceutical Industries Inc. | 112 | $2,030 |
| Arcutis Biotherapeutics, Inc. | 65 | $1,712 |
| LEO Pharma Inc. | 97 | $1,237 |
| Pfizer | 74 | $1,097 |
| E.r. Squibb & Sons, L.L.C. | 79 | $953 |
| Dermavant Sciences, Inc. | 65 | $851 |
| Novartis | 52 | $806 |
| Journey Medical Corporation | 20 | $736 |
| Lilly USA, LLC | 48 | $663 |
| Regeneron Healthcare Solutions, Inc. | 42 | $585 |
| Amgen | 28 | $448 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 23 | $406 |
| Almirall LLC | 22 | $355 |
| VYNE Pharmaceuticals Inc. | 28 | $295 |
| UCB, Inc. | 14 | $236 |
| Mayne Pharma Commercial LLC | 3 | $126 |
| EPI Health, LLC | 8 | $109 |
| Helsinn Therapeutics (U.S.), Inc. | 6 | $95 |
| Fidia Pharma USA Inc. | 2 | $39 |
| Boehringer Ingelheim | 3 | $38 |
| Blueprint Medicines Corporation | 2 | $32 |
| Nabriva Therapeutics, PLC | 2 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Sanofi US Services Inc. | 1 | $17 |
| Strata Skin Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$175,892 in reported general payments places this provider in the 95th percentile of 573 medical providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 20 | $266,558 |
| OtezlaApremilast | 18 | $107,458 |
| OpzeluraRuxolitinib Phosphate | 42 | $105,844 |
| Dupixent PenDupilumab | 11 | $41,793 |
| Clindamycin Phos-TretinoinClindamycin/Tretinoin | 13 | $7,784 |
| Pimecrolimus | 18 | $5,532 |
| Clindamycin-Benzoyl PeroxideClindamycin Phos/Benzoyl Perox | 11 | $5,113 |
| Metronidazole | 56 | $3,213 |
| Tacrolimus | 23 | $2,108 |
| Clobetasol Propionate | 37 | $2,107 |
| Tretinoin | 24 | $1,989 |
| Azelaic Acid | 15 | $1,634 |
| CiclopiroxCiclopirox Olamine | 58 | $1,595 |
| Betamethasone Dipropionate | 39 | $1,542 |
| Triamcinolone Acetonide | 85 | $1,404 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $2,886 | $266,55820 claims |
| AmgenOtezla | $448 | $107,45818 claims |
| Incyte CorporationOpzelura | $23,695 | $105,84442 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 medical providers in New Jersey.
Other medical in Verona
- Anita FoxVerona$17K
- Gabriela Plesek-AndiaVerona$13K
- Christinna DelgenioColts Neck$114K
- Therese CasasKinnelon$16K
- Joseph CollettiLinwood$16K
- Melissa MiaoKearny$14K
- Stephanie PhillipsMarlton$12K
- Sean AdairCape May Court House$12K
- Shane CourtneyLinwood$11K
- Garland LeeWest Orange$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.